Globals - global omic biomarker research for ALS

The Defense Health Agency (DHA) awarded $939,325 to the Weizmann Institute of Science on November 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to support the GLOBALS (Global Omic Biomarker Research for ALS) initiative. This three-year project, extending through October 31, 2028, funds advanced biomedical research focused on discovering and developing omic biomarkers for amyotrophic lateral sclerosis (ALS). The research leverages Weizmann Institute's specialized capabilities in computational biology, laboratory analysis, and biomarker discovery to advance understanding of this neurodegenerative disease and support the development of innovative diagnostic and therapeutic approaches relevant to military and public health objectives.

The Military Medical Research and Development program supports hypothesis-driven research designed to transform healthcare for military service members and the American public through innovative medical solutions. As part of this portfolio, the GLOBALS award represents the program's emphasis on neurodegenerative disease biomarker development and precision medicine approaches. The Weizmann Institute, a tax-exempt Israeli research institution with established federal relationships, will conduct this research at its Rehovot campus, contributing to DHA's broader investment in basic and applied biomedical research addressing critical health challenges.